HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Cites Latisse Web Site For Implying Eyelash Growth Drug Is A Cosmetic

This article was originally published in The Rose Sheet

Executive Summary

Allergan's consumer Web site for its eyelash growth drug Latisse certainly caught FDA's eye, leading the agency to issue a Sept. 10 "untitled" letter that cautions against promoting a drug like a cosmetic

You may also be interested in...



Coty/Rimmel Targeted With Suit Over Lash Accelerator Claims

Lawsuit seeking class-action status against Coty alleges that lengthening and multiplying claims for the firm’s Rimmel London Lash Accelerator are “false, misleading and are reasonably likely to deceive the public.”

FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims

An April 18 FDA warning letter to Lifetech Resources LLC demonstrates that cosmetics firms will be held accountable when their websites feature third-party claims and testimonials that cross into drug marketing territory.

FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims

An April 18 FDA warning letter to Lifetech Resources LLC demonstrates that cosmetics firms will be held accountable when their websites feature third-party claims and testimonials that cross into drug marketing territory.

Related Content

UsernamePublicRestriction

Register

RS016438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel